Jason Casselman, DO
Allergy & Immunology · Richmond, INNPI 1538456462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $550 and has fallen 52.9% since, to $259 in 2025. That places this record below the midpoint for allergy & immunology clinicians in IN, where the typical reported total is $4,393.
Across 111 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$518
- AstraZeneca$488
- GSK$325
- Novartis$233
- Sanofi$160
- Amgen$144
- plus $415 from 11 others
What the payments were for
- Food & beverage$2,16395%
- Education$1195%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 17 | $518 |
| AstraZeneca | 27 | $488 |
| GSK | 15 | $325 |
| Novartis | 15 | $233 |
| Sanofi | 6 | $160 |
| Amgen | 7 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $115 |
| CSL Behring | 5 | $90 |
| Grifols USA, LLC | 2 | $42 |
| Boehringer Ingelheim | 2 | $30 |
| Kaleo, Inc. | 2 | $28 |
| Genentech USA, Inc. | 1 | $23 |
| Pfizer | 1 | $20 |
| Stryker | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,282 in reported general payments places this provider in the 35th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 106 | $400,942 |
| TezspireTezepelumab-Ekko | 60 | $263,139 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 53 | $231,367 |
| XembifyImmune Globulin,gamma(Igg)klhw | 37 | $200,783 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $182,041 |
| XolairOmalizumab | 56 | $150,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 195 | $138,130 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 31 | $96,073 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $46,928 |
| GastrocromCromolyn Sodium | 15 | $25,500 |
| Spiriva RespimatTiotropium Bromide | 40 | $22,147 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $12,931 |
| Azelastine Hcl | 365 | $9,899 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,516 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort, Bevespi Aerosphere | $488 | $281,322129 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia, Cuvitru | $115 | $278,11444 claims |
| CSL BehringHizentra | $90 | $231,36753 claims |
| Grifols USA, LLCXembify | $42 | $200,78337 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $325 | $198,696325 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $30 | $27,92652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Richmond
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
- Douglas NeeldFort Wayne$77K
- Pooja PatelMerrillville$55K
- Mitchell SmithGreenwood$33K
- Ketan ShethLafayette$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.